Characteristic of 738 patients with Ph+ ALL who received allo-SCT
| Characteristic . | Non-imatinib cohort (n = 196) . | Imatinib cohort (n = 542) . | P . |
|---|---|---|---|
| Age at SCT, years (%) | |||
| ≤29 | 48 (24) | 99 (18) | |
| 30-54 | 140 (71) | 365 (67) | |
| ≥55 | 8 (4) | 78 (14) | |
| Median | 39 | 42 | <.001 |
| Gender (male/female) | 109/87 | 293/249 | .708 |
| Donor status (%) | |||
| Related | 121 (62) | 178 (33) | |
| Unrelated | 75 (38) | 364 (67) | <.001 |
| HLA disparity (%) | |||
| Matched | 139 (71) | 330 (61) | |
| Mismatched | 56 (29) | 211 (39) | |
| Unknown | 1 (0) | 1 (0) | .010 |
| Stem cell source (%) | |||
| Bone marrow | 151 (77) | 345 (64) | |
| Peripheral blood | 36 (18) | 86 (16) | |
| Cord blood | 9 (5) | 111 (20) | <.001 |
| PS at SCT (%) | |||
| 0 | 70 (36) | 311 (57) | |
| 1-4 | 45 (23) | 218 (40) | |
| Unknown | 81 (41) | 13 (2) | .632 |
| Days from diagnosis to SCT (%) | |||
| <180 | 94 (48) | 286 (53) | |
| ≤180 | 98 (50) | 255 (47) | |
| Unknown | 4 (2) | 1 (0) | .352 |
| BCR-ABL subtype (%) | |||
| Major | 24 (12) | 70 (13) | |
| Minor | 69 (35) | 352 (65) | |
| Major and minor | 1 (0) | 18 (3) | |
| Unknown | 102 (52) | 102 (19) | .039 |
| Donor recipient gender match (%) | |||
| Male-male | 43 (22) | 180 (33) | |
| Male-female | 38 (19) | 129 (24) | |
| Female-male | 35 (18) | 97 (18) | |
| Female-female | 33 (17) | 111 (20) | |
| Unknown | 47 (24) | 25 (5) | .463 |
| Conditioning regimen (%) | |||
| Reduced intensity | 1 (1) | 44 (8) | |
| Myeloabrative | 121 (62) | 479 (88) | |
| Unknown | 74 (38) | 19 (4) | <.001 |
| WBC at diagnosis (%) | |||
| <30 000/μL | 109 (56) | 288 (53) | |
| ≤30 000/μL | 74 (38) | 247 (46) | |
| Unknown | 13 (7) | 7 (1) | .178 |
| GVHD prophylaxis (%) | |||
| CyA/methotrexate | 133 (68) | 228 (42) | |
| Tacrorimus/methotrexate | 46 (23) | 266 (49) | |
| Other/unknown | 17 (9) | 48 (9) | <.001 |
| Cytogenetics (%) | |||
| t(9;22) only | 180 (92) | 461 (85) | |
| Other abnormality | 16 (8) | 81 (15) | .016 |
| ABO blood type disparity (%) | |||
| Match | 65 (33) | 266 (49) | |
| Minor | 24 (12) | 119 (22) | |
| Major | 37 (19) | 152 (28) | |
| Unknown | 70 (36) | 5 (1) | .747 |
| Transplant year (%) | |||
| 1990-2005 | 183 (93) | 139 (26) | |
| 2006-2010 | 13 (7) | 403 (74) | <.001 |
| MRD status at SCT | |||
| Positive | 44 (22) | 144 (27) | |
| Negative | 23 (12) | 256 (47) | <.001 |
| Characteristic . | Non-imatinib cohort (n = 196) . | Imatinib cohort (n = 542) . | P . |
|---|---|---|---|
| Age at SCT, years (%) | |||
| ≤29 | 48 (24) | 99 (18) | |
| 30-54 | 140 (71) | 365 (67) | |
| ≥55 | 8 (4) | 78 (14) | |
| Median | 39 | 42 | <.001 |
| Gender (male/female) | 109/87 | 293/249 | .708 |
| Donor status (%) | |||
| Related | 121 (62) | 178 (33) | |
| Unrelated | 75 (38) | 364 (67) | <.001 |
| HLA disparity (%) | |||
| Matched | 139 (71) | 330 (61) | |
| Mismatched | 56 (29) | 211 (39) | |
| Unknown | 1 (0) | 1 (0) | .010 |
| Stem cell source (%) | |||
| Bone marrow | 151 (77) | 345 (64) | |
| Peripheral blood | 36 (18) | 86 (16) | |
| Cord blood | 9 (5) | 111 (20) | <.001 |
| PS at SCT (%) | |||
| 0 | 70 (36) | 311 (57) | |
| 1-4 | 45 (23) | 218 (40) | |
| Unknown | 81 (41) | 13 (2) | .632 |
| Days from diagnosis to SCT (%) | |||
| <180 | 94 (48) | 286 (53) | |
| ≤180 | 98 (50) | 255 (47) | |
| Unknown | 4 (2) | 1 (0) | .352 |
| BCR-ABL subtype (%) | |||
| Major | 24 (12) | 70 (13) | |
| Minor | 69 (35) | 352 (65) | |
| Major and minor | 1 (0) | 18 (3) | |
| Unknown | 102 (52) | 102 (19) | .039 |
| Donor recipient gender match (%) | |||
| Male-male | 43 (22) | 180 (33) | |
| Male-female | 38 (19) | 129 (24) | |
| Female-male | 35 (18) | 97 (18) | |
| Female-female | 33 (17) | 111 (20) | |
| Unknown | 47 (24) | 25 (5) | .463 |
| Conditioning regimen (%) | |||
| Reduced intensity | 1 (1) | 44 (8) | |
| Myeloabrative | 121 (62) | 479 (88) | |
| Unknown | 74 (38) | 19 (4) | <.001 |
| WBC at diagnosis (%) | |||
| <30 000/μL | 109 (56) | 288 (53) | |
| ≤30 000/μL | 74 (38) | 247 (46) | |
| Unknown | 13 (7) | 7 (1) | .178 |
| GVHD prophylaxis (%) | |||
| CyA/methotrexate | 133 (68) | 228 (42) | |
| Tacrorimus/methotrexate | 46 (23) | 266 (49) | |
| Other/unknown | 17 (9) | 48 (9) | <.001 |
| Cytogenetics (%) | |||
| t(9;22) only | 180 (92) | 461 (85) | |
| Other abnormality | 16 (8) | 81 (15) | .016 |
| ABO blood type disparity (%) | |||
| Match | 65 (33) | 266 (49) | |
| Minor | 24 (12) | 119 (22) | |
| Major | 37 (19) | 152 (28) | |
| Unknown | 70 (36) | 5 (1) | .747 |
| Transplant year (%) | |||
| 1990-2005 | 183 (93) | 139 (26) | |
| 2006-2010 | 13 (7) | 403 (74) | <.001 |
| MRD status at SCT | |||
| Positive | 44 (22) | 144 (27) | |
| Negative | 23 (12) | 256 (47) | <.001 |
CyA, cyclospoline.